Baseline use of β-blockers, calcium channel blockers, statins, loop diuretics, and potassium-lowering agents was higher in participants with stage 4 CKD, whereas use of metformin and sodium-glucose cotransporter-2 inhibitor at baseline was lower (Supplemental Table 3). This evidence concerns the gene SLC5A2 and chronic kidney disease.